Key Development
AstraZeneca and Daiichi Sankyo have secured an important access milestone in the UK, with Enhertu (trastuzumab deruxtecan) cleared for NHS reimbursement in England for eligible patients with HER2-low advanced or metastatic breast cancer. Around 1,000 women per year are expected to qualify for treatment. Enhertu has been available in Scotland since 2023, while the companies are now pursuing access in Wales and Northern Ireland.
The significance is that Enhertu is not a medicine still trying to establish clinical relevance. DESTINY-Breast04 demonstrated substantial improvements in progression-free and overall survival compared with physician’s-choice chemotherapy. Across the overall trial population, median overall survival reached 23.4 months with trastuzumab deruxtecan versus 16.8 months with chemotherapy.
The barrier was economics rather than efficacy. In 2024, NICE declined to recommend the treatment for HER2-low disease after concluding that its cost-effectiveness estimates remained above the level considered an acceptable use of NHS resources, despite recognising disease severity, unmet need and the drug’s innovative nature. Reuters reported that the latest decision follows changes in Britain’s cost-effectiveness methodology and a commercial agreement whose financial terms remain confidential.
Why It Matters
- Clinical innovation and market access are becoming equally important capabilities. Strong survival data alone do not guarantee adoption when payer economics remain unfavourable.
- HER2-low is expanding the addressable market for targeted oncology. A population historically managed largely as HER2-negative disease can now benefit from HER2-directed ADC therapy, reshaping both diagnostic and treatment pathways.
- Enhertu is evolving into a platform oncology asset. Its footprint continues to expand across settings and tumour types; in September 2026, the EU also approved Enhertu plus pertuzumab as first-line treatment for HER2-positive metastatic breast cancer.
- The NHS decision matters beyond approximately 1,000 annual patients. It provides another real-world case of how public healthcare systems can reconcile innovation, survival benefit and affordability.
Healthcare Insight Analysis
The strategic lesson is the widening gap between regulatory approval and reimbursed access.
Regulators primarily determine whether a medicine’s benefit-risk profile supports approval. Public payers must answer a different question: does the incremental benefit justify the incremental expenditure relative to competing uses of limited healthcare resources?
Enhertu illustrates that distinction unusually clearly. NICE had already accepted that the medicine delayed disease progression and improved survival. What failed in 2024 was the economic case. The eventual reversal demonstrates how pricing architecture, HTA methodology and commercial negotiation can materially alter the addressable market even when the underlying clinical evidence has long been compelling.
For pharmaceutical companies, competitive advantage in oncology therefore increasingly extends beyond the molecule itself. Health economics, reimbursement strategy, real-world evidence and payer negotiation are becoming core components of product strategy.
There is also a downstream diagnostic implication. As HER2-directed ADCs move beyond conventionally HER2-positive tumours into HER2-low disease, accurate biomarker classification becomes more commercially and clinically consequential. Diagnostic infrastructure increasingly determines which patients can enter the treatment pathway.
Market Implications
For AstraZeneca and Daiichi Sankyo: NHS England adds an important reimbursed market for an increasingly central global oncology asset. The broader strategic value may lie in demonstrating a workable access model for other HTA-driven markets.
For the ADC sector: competition is moving beyond whether ADC technology works. The next question is which therapies can generate enough incremental clinical value to sustain premium pricing.
For healthcare payers: confidential commercial arrangements and evolving value-assessment frameworks may become increasingly important mechanisms for absorbing high-cost cancer innovation without abandoning budget discipline.
For the wider healthcare ecosystem: diagnostics, biomarker testing, health economics and reimbursement capabilities are becoming integral parts of the precision-oncology value chain.